REPREP2: Impact of a Predictive Score of Bowel Preparation Quality in Clinical Practice

Sponsor
Hospital Universitario de Canarias (Other)
Overall Status
Completed
CT.gov ID
NCT03830489
Collaborator
(none)
260
1
2
8.8
29.5

Study Details

Study Description

Brief Summary

This is a single center randomized controlled trial to compare the colon cleansing quality determined by the Boston Bowel Preparation Scale achieved by two strategies in patients with high risk of poor colon cleansing defined as those patients with a score> 1.225 following a predictive score previously published: one group will receive an intensified split-dose 4 L polyethylene glycol solution (PEG) plus bisacodyl and 3 days of fiber-free diet and the other group a split-dose 2 L PEG solution with ascorbic plus bisacodyl and 1 day of fiber-free diet.

Patients with a score ≤ 1.225 will receive a split-dose 2 L PEG solution with ascorbic plus bisacodyl and 1 day of fiber-free diet.

Condition or Disease Intervention/Treatment Phase
  • Drug: polyethylene glycol
  • Drug: polyethylene glycol plus ascorbic acid
Phase 4

Detailed Description

This is a prospective, randomized, single-blind phase IV study in which all outpatients scheduled for a colonoscopy will be given a different bowel cleansing strategy (conventional or intensified) according to a scoring system already validated in the investigator's center, designed with variables independently associated with poor bowel cleansing, constipation, abdominal/pelvic surgery, comorbidity and to be on antidepressant treatment. According to this system, a score equal to or less than 1.225, predicts with a high confidence (negative predictive value = 88%) a suitable cleansing quality with a standard preparation protocol. Therefore, these subjects will be advised of a conventional preparation (low fiber diet the day before the examination and low volume preparation consisting of 2 L of PEG with ascorbic acid). Subjects with a score greater than 1.225 will be randomized to receive an intensive bowel preparation (low fiber diet three days prior to colonoscopy and large bowel preparation consisting of 4 L PEG with bisacodyl) or a conventional one (low fiber diet the day before the examination and 2 L of PEG with ascorbic acid). The choice of low-volume preparation as a control is supported by the absence of significant differences in quality of cleanliness in patients with a score > 1.225 among patients prepared with high or low volume and that low volume preparation appears to improve tolerance and compliance.

A researcher will offer to participate in the study to all outpatients with a scheduled colonoscopy, who meet all the inclusion criteria and none of the exclusion criteria. The researchers will explain the purpose of the study and will ask to sign the informed consent. They will give verbal and written information on the bowel preparation strategy. Thus, according to the allocation group, participants must comply with a large volume cleansing strategy or a conventional one. For patients with a low score (≤ 1.225) a conventional preparation will be recommended.

Patients must complete a baseline questionnaire at the inclusion visit and another questionnaire at the colonoscopy visit.

The hypothesis of the study is that in patients with a high risk of poor bowel preparation, the large bowel based preparation strategy is superior to the conventional bowel preparation in achieving an acceptable bowel cleansing assessed by a validated scale (Boston Bowel Preparation Score).

Study Design

Study Type:
Interventional
Actual Enrollment :
260 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Investigator)
Masking Description:
Only the endoscopists in charge of rating the bowel cleansing during the colonoscopy will be masked
Primary Purpose:
Other
Official Title:
Intensive High-volume Bowel Cleansing Regimen Versus Low-volume Bowel Regimen in Patients With a High Risk of Poor Colonic Cleansing Following a Validated Predictive Score
Actual Study Start Date :
Feb 4, 2019
Actual Primary Completion Date :
Oct 21, 2019
Actual Study Completion Date :
Oct 30, 2019

Arms and Interventions

Arm Intervention/Treatment
Experimental: Large volume based preparation

This strategy will consist of split dose 4 L polyethylene glycol plus 10 mg bisacodyl plus 3 days of fiber-free diet.

Drug: polyethylene glycol
The experimental arm will take 4 L polyethylene glycol solution (PEG) in split dose plus bisacodyl and 3 days of fiber-free diet

Active Comparator: Low volume based preparation

This strategy will consist of split dose 2 L polyethylene glycol plus Ascorbic acid plus 1 day of fiber-free diet

Drug: polyethylene glycol plus ascorbic acid
The control arm will take 2 L polyethylene glycol solution (PEG) plus ascorbic acid in split dose plus 1 day of fiber-free diet

Outcome Measures

Primary Outcome Measures

  1. Boston Bowel Preparation Scale [8 months]

    This scale goes from 0 (no preparation) to 3 points (excellent preparation) in the three segments of the colon (proximal, transverse and distal). The maximum score is 9 points

Secondary Outcome Measures

  1. Proportion of polyps detected in each arm [8 months]

    Number of polyps in one arm/total of polyps detected

  2. Tolerance to bowel preparation [8 months]

    It will be subjective and assessed by a visual analog scale (0 very bad, 10 excellent)

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Age ≥ 18 years

  • Outpatient colonoscopy

  • Willing to participate (informed consent signed).

Exclusion Criteria:
  • Intestinal perforation

  • Poorly controlled arterial hypertension (HTAS> 180 HTAD> 100)

  • Congestive heart failure

  • NYHA III-IV

  • Acute hepatic failure

  • End-stage renal disease (creatinine <15 ml / min dialysis or pre-dialysis)

  • Pregnancy or breastfeeding

  • Known hypersensitivity reaction to drug components

  • Phenylketonuria or Glucose-6-phosphate dehydrogenase deficiency

  • Dementia with difficulty in intake of Preparation

  • Past history of poor bowel preparation colonic cleanliness

  • Inability to follow the instructions

Contacts and Locations

Locations

Site City State Country Postal Code
1 Department of Gastroenterology La Laguna S/C De Tenerife Spain 38320

Sponsors and Collaborators

  • Hospital Universitario de Canarias

Investigators

  • Principal Investigator: Goretti Hernandez, MD, Hospital Universitario de Canarias

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Hospital Universitario de Canarias
ClinicalTrials.gov Identifier:
NCT03830489
Other Study ID Numbers:
  • Score-guided colon cleansing
First Posted:
Feb 5, 2019
Last Update Posted:
Mar 13, 2020
Last Verified:
Mar 1, 2020
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Product Manufactured in and Exported from the U.S.:
No
Keywords provided by Hospital Universitario de Canarias
Additional relevant MeSH terms:

Study Results

No Results Posted as of Mar 13, 2020